Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID:
15855581
2.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators.

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984
3.

Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.

Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H; CAFE and ASCOT Investigators.

Circulation. 2009 Jan 6;119(1):53-61. doi: 10.1161/CIRCULATIONAHA.108.785915. Epub 2008 Dec 22.

4.

Reduction in cardiovascular events with atorvastatin in type 2 diabetes.

Clearfield M.

Curr Atheroscler Rep. 2006 Jan;8(1):9-10. No abstract available.

PMID:
16455007
6.

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators.

Eur Heart J. 2011 Oct;32(20):2525-32. doi: 10.1093/eurheartj/ehr333. Epub 2011 Aug 28.

PMID:
21873710
7.

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, McInnes G, Mehlsen J, Nieminem M, O'Brien E, Ostergren J; ASCOT Steering Committee Members.

Eur Heart J. 2006 Dec;27(24):2982-8. Epub 2006 Dec 4. Erratum in: Eur Heart J. 2007 Jan;28(1):142.

PMID:
17145722
8.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
9.

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA; CARDS Study Investigators.

Diabetes Care. 2006 Nov;29(11):2378-84.

PMID:
17065671
11.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Drugs. 2004;64 Suppl 2:43-60.

PMID:
15765890
13.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators.

Lancet. 2003 Apr 5;361(9364):1149-58.

PMID:
12686036
15.

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.

Am J Cardiol. 2005 Sep 5;96(5A):39F-44F. Review.

PMID:
16126022
16.

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien ET, Ostergren J; ASCOT Investigators.

Eur Heart J. 2008 Feb;29(4):499-508. doi: 10.1093/eurheartj/ehm583. Epub 2008 Jan 5.

PMID:
18175773
17.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.

18.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
19.

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT investigators.

Eur J Cardiovasc Prev Rehabil. 2005 Feb;12(1):29-36.

PMID:
15703503
20.

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group.

Diabetes Care. 2003 Oct;26(10):2713-21.

PMID:
14514569

Supplemental Content

Support Center